Short non-diabetic data support remaining at 2.5 mg when weight and insulin-resistance markers are already moving and tolerability favors a hold. The label still positions 2.5 mg as the starter before 5 mg, so it is a defensible low-dose floor for selected users rather than a replacement for the 5 mg obesity-trial floor
You should consult your GP for a formal diagnosis, which may require a different treatment plan as per NHS guidelines
Its original purpose was to stop excessive bleeding during surgery, trauma, or heavy menstrual cycles by preventing the breakdown of blood clots
Mobile phase gradient: 0-0.1 min, 100% B
It is commonly accompanied by hyperlipidemia which results from a disbalance between the rates of fatty acids synthesis and degradation and is characterized by elevated total cholesterol and low-density lipoprotein-cholesterol (LDL-C), thus providing the substrate for ROS-mediated lipid peroxidation (6366)
Dosing Protocols: Research-Grade Administration Ranges AOD-9604 dosing in published literature ranges from 250mcg to 1mg per subcutaneous injection, administered once daily or divided into twice-daily doses depending on study design